Yun Yen - Jun 30, 2023 Form 4 Insider Report for LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)

Role
Director
Signature
/s/ Yun Yen
Stock symbol
LIXT
Transactions as of
Jun 30, 2023
Transactions value $
$0
Form type
4
Date filed
7/7/2023, 10:58 AM
Previous filing
Aug 3, 2022
Next filing
Jul 2, 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LIXT Options to Purchase Common Stock Award $0 +10K $0.00 10K Jun 30, 2023 Common 10K $5.88 Direct F1
holding LIXT Options to Purchase Common Stock 10K Jun 30, 2023 Common 10K $7.45 Direct
holding LIXT Options to Purchase Common Stock 10K Jun 30, 2023 Common 10K $30.30 Direct
holding LIXT Options to Purchase Common Stock 5K Jun 30, 2023 Common 5K $32.10 Direct
holding LIXT Warrants to Purchase Common Stock 5.26K Jun 30, 2023 Common 5.26K $57.00 By Sino-American Cancer FDD
holding LIXT Options to Purchase Common Stock 3.33K Jun 30, 2023 Common 3.33K $16.80 Direct
holding LIXT Options to Purchase Common Stock 833 Jun 30, 2023 Common 833 $66.00 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Effective June 30, 2023, the reporting person was granted stock options to purchase an aggregate of 10,000 shares, vesting on the last day of each subsequent quarter until fully vested (e.g. vesting to start on September 30, 2023). Effective June 2, 2023, the Issuer effected a 1-for-10 reverse split of its outstanding shares of common stock. Accordingly, the exercise price and the amount of underlying shares of Common Stock set forth above have been adjusted to reflect the reverse split.